Proteolysis of IGFBPs is an active part for the control of IGF-bioactivity during pregnancy, cancer or other age related diseases. During proteolysis IGFBP-fragments are formed, with low affinities for the IGFs and the IGFs are released from their binding sites. Free IGFs have direct access to their receptors and thus are considered as being more bioactive if compared to IGFBP-bound IGFs.
[ Downloads ]
Pitfalls of current diagnostic: Proteolysis of IGFBPs
Current immunological systems may detect both intact and fragmented IGFBPs and therefore, IGFBP-fragments are potential confounding factors for current IGFBP-biomarker research. By contrast, the innovative quantitative Western Ligand Blotting (qWLB) exclusively quantifies intact and biologically active IGFBPs since the IGF-ligand do not bind to IGFBP-fragments. Novel qWLB is perfectly matching the different conditions of IGFBP-physiology. This crucially increases the biomarker quality IGFBP-data generated by qWLB.